TP53 and myelodysplastic syndrome: TP53 mutations are of particular concern as they represent one of the highest-risk subsets of MDS patients with significantly reduced survival, complex karyotypes, heterogeneity in allelic states, drug resistance, and clinical outcomes (8, 9).